Long COVIDREWORK-COVNCT07881029
Cognitive Impairment and Return to Work in Long COVID
An observational study of Long COVID, run by Hopitaux de Saint-Maurice at 1 site in France.
Trial summary
This retrospective, single-center observational study investigates the relationship between cognitive performance and return to work in patients with Long COVID. The study includes patients followed in the Long COVID day hospital at Hôpitaux Paris Est Val-de-Marne who underwent a neuropsychological assessment as part… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Long COVID
- How many people
- 55 participants
- Where
- 1 siteFrance
- Study dates
- 1 Aug 2026to 1 Sep 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult patients with Long COVID followed in the Long COVID day hospital at Hôpitaux Paris Est Val-de-Marne who underwent a neuropsychological assessment as part of routine clinical care. The study retrospectively reuses existing clinical, neuropsychological, psychological, and occupational data. For analyses of return to work, patients were professionally active before COVID and had employment-status data available at 6-month follow-up.
Who may be able to join
- Positive PCR test for SARS-CoV-2 infection.
- Diagnosis of Long COVID according to Haute Autorité de Santé (HAS) criteria.
- French-speaking.
- Neuropsychological assessment available and exploitable.
- For the primary return-to-work analysis: professionally active before COVID and employment status at 6 months available.
Who cannot join
- History of psychiatric or neurological disorders.
- Patient opposition to the use of their data.
- No exploitable neuropsychological assessment.
- No employment-status data available at 6 months for the primary analysis.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Exploring the Relationship Between Cognitive Impairment and Return to Work in Long COVID
This retrospective, single-center observational study investigates the relationship between cognitive performance and return to work in patients with Long COVID. The study includes patients followed in the Long COVID day hospital at Hôpitaux Paris Est Val-de-Marne who underwent a neuropsychological assessment as part of routine care. Cognitive performance in executive functions, attention, memory, and processing speed is analyzed in relation to employment status at the time of assessment and six months later.
Read the detailed description
Long COVID is characterized by persistent symptoms following acute SARS-CoV-2 infection and may include cognitive difficulties affecting attention, memory, executive functions, and processing speed. These impairments may interfere with daily functioning and the ability to maintain or resume professional activity.
This retrospective single-center study is based on the reuse of routinely collected healthcare data from patients followed in the Long COVID day hospital of Hôpitaux Paris Est Val-de-Marne. No additional examinations, questionnaires, or data collection are performed specifically for the research.
The primary objective is to investigate the association between cognitive performance assessed during neuropsychological evaluation and return to professional activity six months later. Secondary objectives are to describe the frequency and profile of cognitive impairments across different cognitive domains, describe return-to-work modalities at six months, compare cognitive performance according to employment status and type of return to work, and explore potential relationships between anxiety and depressive symptoms, cognitive performance, and occupational outcomes.
The analyzed data include sociodemographic and clinical characteristics, neuropsychological test scores assessing attention, executive functions, short- and long-term memory, and processing speed, as well as anxiety and depression questionnaire scores. Employment status is assessed at the time of neuropsychological evaluation and six months later, including no return to work, partial return, or full return.
- Conditions
- Long COVID
- Keywords
- Long COVID, Cognitive impairment, Neuropsychological assessment, Work ability, Employment status
- Medical subject headings
- Post-Acute COVID-19 Syndrome, Cognitive Dysfunction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patients with Long COVID | Adult patients with Long COVID followed in the long COVID day hospital at Hôpitaux Paris Est Val-de-Marne who underwent a neuropsychological assessment as part of routine care and met the study eligibility criteria |
What is being measured
The primary outcome is the main question the study is designed to answer.
Processing Speed According to Return-to-Work Status at 6 Months
Processing speed assessed using the Coding subtest of the WAIS-IV at the neuropsychological assessment, compared according to return-to-work status at 6 months.
Measured: From the neuropsychological assessment to 6-month follow-up
Verbal Short-Term Memory According to Return-to-Work Status at 6 Months
Verbal short-term memory assessed using the auditory-verbal span from the WAIS-IV, compared according to return-to-work status at 6 months.
Measured: From the neuropsychological assessment to 6-month follow-up
Visual Short-Term Memory According to Return-to-Work Status at 6 Months
Visual short-term memory assessed using the visuospatial span from the MEM-III, compared according to return-to-work status at 6 months.
Measured: From the neuropsychological assessment to 6-month follow-up
Long-Term Verbal Memory According to Return-to-Work Status at 6 Months
Long-term verbal memory was assessed using the RL/RI-16 test. Measures included retrieval (sum of the three free-recall trials), storage (sum of the three total-recall trials and recognition), and long-term consolidation (delayed free and total recall). Performance was compared according to return-to-work status at 6 months.
Measured: From the neuropsychological assessment to 6-month follow-up
Selective Attention According to Return-to-Work Status at 6 Months
Selective attention was assessed using the D2 or D2-R test, based on response accuracy and errors. Performance was compared according to return-to-work status at 6 months.
Measured: From the neuropsychological assessment to 6-month follow-up
Sustained Attention According to Return-to-Work Status at 6 Months
Sustained attention was assessed using the D2 or D2-R test, based on concentration performance. Performance was compared according to return-to-work status at 6 months.
Measured: From the neuropsychological assessment to 6-month follow-up
Mental Flexibility According to Return-to-Work Status at 6 Months
Mental flexibility was assessed using the Trail Making Test (TMT), including errors on Part B and the B-A completion-time difference. Performance was compared according to return-to-work status at 6 months.
Measured: From the neuropsychological assessment to 6-month follow-up
Inhibition According to Return-to-Work Status at 6 Months
Inhibitory control was assessed using the Stroop Test, including errors on the interference condition and the interference time adjusted for naming time. Performance was compared according to return-to-work status at 6 months.
Measured: From the neuropsychological assessment to 6-month follow-up
Secondary outcomes (5)
Frequency of Below-Norm Cognitive Performance by Domain Using Standardized Neuropsychological Tests
Frequency of participants with cognitive performance below normative values in each assessed domain. Processing speed was assessed with the WAIS-IV Coding subtest; verbal short-term memory with the WAIS-IV auditory-verbal span; visual short-term memory with the MEM-III visuospatial span; long-term verbal memory with the RL/RI-16; selective and sustained attention with the D2/D2-R; and executive functions with the Trail Making Test and Stroop Test. Classification as below normative values was based on the normative interpretation applicable to each test.
Measured: Baseline
Number of Participants According to Return-to-Work Status at 6 Months
Number of participants according to return-to-work status at 6-month follow-up: return to work or no return to work. Among participants who returned to work, partial and full return to work will also be described.
Measured: 6 months after the neuropsychological assessment
Cognitive Performance According to Employment Status at Neuropsychological Assessment and at 6 Months
Cognitive performance was assessed using standardized neuropsychological tests covering processing speed (WAIS-IV Coding), verbal short-term memory (WAIS-IV auditory-verbal span), visual short-term memory (MEM-III visuospatial span), long-term verbal memory (RL/RI-16), attention (D2/D2-R), mental flexibility (Trail Making Test), and inhibition (Stroop Test). Performance was compared according to employment status at the neuropsychological assessment and at 6-month follow-up.
Measured: From the neuropsychological assessment to 6-month follow-up
Anxiety Symptoms Assessed With the State-Trait Anxiety Inventory (STAI)
Anxiety symptoms were assessed using the State-Trait Anxiety Inventory (STAI), including state and trait anxiety measures.
Measured: Baseline
Depressive Symptoms Assessed With the Beck Depression Inventory (BDI)
Depressive symptoms were assessed using the Beck Depression Inventory (BDI).
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Oct 2026
- Study start1 Aug 2026
- Primary completion1 Sep 2026
- Study completion1 Sep 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Long COVIDStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 55 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hopitaux de Saint-Maurice
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07881029
- Sponsor's protocol ID
- REWORK-COV
- Acronym
- REWORK-COV
- Status last verified
- Oct 2026
- First submitted
- 29 Sep 2026
- Last updated
- 19 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Exploring the Relationship Between Cognitive Impairment and Return to Work in Long COVID
- ClinicalTrials.gov ID
- NCT07881029
- Acronym / sponsor ID
- REWORK-COV / REWORK-COV
- Conditions
- Long COVID
- Keywords
- Long COVID, Cognitive impairment, Neuropsychological assessment, Work ability, Employment status
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 55 participants (actual)
- Lead sponsor
- Hopitaux de Saint-MauriceUniversity, hospital or other
- Study start
- 1 Aug 2026 (actual)
- Primary completion
- 1 Sep 2026 (actual)
- Study completion
- 1 Sep 2026 (actual)
- First posted
- 19 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This retrospective, single-center observational study investigates the relationship between cognitive performance and return to work in patients with Long COVID. The study includes patients followed in the Long COVID day hospital at Hôpitaux Paris Est Val-de-Marne who underwent a neuropsychological assessment as part of routine care. Cognitive performance in executive functions, attention, memory, and processing speed is analyzed in relation to employment status at the time of assessment and six months later.
Detailed description
Long COVID is characterized by persistent symptoms following acute SARS-CoV-2 infection and may include cognitive difficulties affecting attention, memory, executive functions, and processing speed. These impairments may interfere with daily functioning and the ability to maintain or resume professional activity.
This retrospective single-center study is based on the reuse of routinely collected healthcare data from patients followed in the Long COVID day hospital of Hôpitaux Paris Est Val-de-Marne. No additional examinations, questionnaires, or data collection are performed specifically for the research.
The primary objective is to investigate the association between cognitive performance assessed during neuropsychological evaluation and return to professional activity six months later. Secondary objectives are to describe the frequency and profile of cognitive impairments across different cognitive domains, describe return-to-work modalities at six months, compare cognitive performance according to employment status and type of return to work, and explore potential relationships between anxiety and depressive symptoms, cognitive performance, and occupational outcomes.
The analyzed data include sociodemographic and clinical characteristics, neuropsychological test scores assessing attention, executive functions, short- and long-term memory, and processing speed, as well as anxiety and depression questionnaire scores. Employment status is assessed at the time of neuropsychological evaluation and six months later, including no return to work, partial return, or full return.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients with Long COVID | – | –Adult patients with Long COVID followed in the long COVID day hospital at Hôpitaux Paris Est Val-de-Marne who underwent a neuropsychological assessment as part of routine care and met the study eligibility criteria |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients with Long COVID followed in the Long COVID day hospital at Hôpitaux Paris Est Val-de-Marne who underwent a neuropsychological assessment as part of routine clinical care. The study retrospectively reuses existing clinical, neuropsychological, psychological, and occupational data. For analyses of return to work, patients were professionally active before COVID and had employment-status data available at 6-month follow-up.
Key inclusion criteria (5 listed)
- Positive PCR test for SARS-CoV-2 infection.
- Diagnosis of Long COVID according to Haute Autorité de Santé (HAS) criteria.
- French-speaking.
- Neuropsychological assessment available and exploitable.
- For the primary return-to-work analysis: professionally active before COVID and employment status at 6 months available.
Key exclusion criteria (4 listed)
- History of psychiatric or neurological disorders.
- Patient opposition to the use of their data.
- No exploitable neuropsychological assessment.
- No employment-status data available at 6 months for the primary analysis.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Processing Speed According to Return-to-Work Status at 6 Months
Time frame: From the neuropsychological assessment to 6-month follow-up
Processing speed assessed using the Coding subtest of the WAIS-IV at the neuropsychological assessment, compared according to return-to-work status at 6 months.
Verbal Short-Term Memory According to Return-to-Work Status at 6 Months
Time frame: From the neuropsychological assessment to 6-month follow-up
Verbal short-term memory assessed using the auditory-verbal span from the WAIS-IV, compared according to return-to-work status at 6 months.
Visual Short-Term Memory According to Return-to-Work Status at 6 Months
Time frame: From the neuropsychological assessment to 6-month follow-up
Visual short-term memory assessed using the visuospatial span from the MEM-III, compared according to return-to-work status at 6 months.
Long-Term Verbal Memory According to Return-to-Work Status at 6 Months
Time frame: From the neuropsychological assessment to 6-month follow-up
Long-term verbal memory was assessed using the RL/RI-16 test. Measures included retrieval (sum of the three free-recall trials), storage (sum of the three total-recall trials and recognition), and long-term consolidation (delayed free and total recall). Performance was compared according to return-to-work status at 6 months.
Selective Attention According to Return-to-Work Status at 6 Months
Time frame: From the neuropsychological assessment to 6-month follow-up
Selective attention was assessed using the D2 or D2-R test, based on response accuracy and errors. Performance was compared according to return-to-work status at 6 months.
Sustained Attention According to Return-to-Work Status at 6 Months
Time frame: From the neuropsychological assessment to 6-month follow-up
Sustained attention was assessed using the D2 or D2-R test, based on concentration performance. Performance was compared according to return-to-work status at 6 months.
Mental Flexibility According to Return-to-Work Status at 6 Months
Time frame: From the neuropsychological assessment to 6-month follow-up
Mental flexibility was assessed using the Trail Making Test (TMT), including errors on Part B and the B-A completion-time difference. Performance was compared according to return-to-work status at 6 months.
Inhibition According to Return-to-Work Status at 6 Months
Time frame: From the neuropsychological assessment to 6-month follow-up
Inhibitory control was assessed using the Stroop Test, including errors on the interference condition and the interference time adjusted for naming time. Performance was compared according to return-to-work status at 6 months.
5 secondary outcomes
Frequency of Below-Norm Cognitive Performance by Domain Using Standardized Neuropsychological Tests
Time frame: Baseline
Number of Participants According to Return-to-Work Status at 6 Months
Time frame: 6 months after the neuropsychological assessment
Cognitive Performance According to Employment Status at Neuropsychological Assessment and at 6 Months
Time frame: From the neuropsychological assessment to 6-month follow-up
Anxiety Symptoms Assessed With the State-Trait Anxiety Inventory (STAI)
Time frame: Baseline
Depressive Symptoms Assessed With the Beck Depression Inventory (BDI)
Time frame: Baseline
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Oct 2026.
Related trials for Long COVID
Not yet recruitingPhase 3
The Study of Brave-LC LDN Treatment Trial
Post-acute COVID-19 Syndrome
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingObservational study
Epigenetic Changes in Long COVID Patients
Long COVID-19 Syndrome, Long COVID Symptoms
Enrolling by invitationPhase 2
Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2
Systemic Inflammation, Neuroinflammation
Not yet recruitingPhase 3
Dapagliflozin for Long COVID Syndrome
COVID - 19, Long COVID Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Long COVID, run by Hopitaux de Saint-Maurice at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Processing Speed According to Return-to-Work Status at 6 Months (time frame: From the neuropsychological assessment to 6-month follow-up). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Oct 2026.